Influenza- and COVID-19-Associated Pulmonary Aspergillosis: Are the Pictures Different?

Reizine, Florian; Pinceaux, Kieran; Lederlin, Mathieu; Autier, Brice; Guegan, Hélène; Gacouin, Arnaud; Luque-Paz, David; Boglione-Kerrien, Christelle; Bacle, Astrid; Le Daré, Brendan; Launey, Yoann; Lesouhaitier, Mathieu; Painvin, Benoit; Camus, Christophe; Mansour, Alexandre; Robert-Gangneux, Florence; Belaz, Sorya; Le Tulzo, Yves; Tadié, Jean-Marc; Maamar, Adel; Gangneux, Jean-Pierre

Invasive pulmonary aspergillosis (IPA) in intensive care unit patients is a major concern. Influenza-associated acute respiratory distress syndrome (ARDS) and severe COVID-19 patients are both at risk of developing invasive fungal diseases. We used the new international definitions of influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA) to compare the demographic, clinical, biological, and radiological aspects of IAPA and CAPA in a monocentric retrospective study. A total of 120 patients were included, 71 with influenza and 49 with COVID-19-associated ARDS. Among them, 27 fulfilled the newly published criteria of IPA: 17/71 IAPA (23.9%) and 10/49 CAPA (20.4%). Kaplan–Meier curves showed significantly higher 90-day mortality for IPA patients overall (p = 0.032), whereas mortality did not differ between CAPA and IAPA patients. Radiological findings showed differences between IAPA and CAPA, with a higher proportion of features suggestive of IPA during IAPA. Lastly, a wide proportion of IPA patients had low plasma voriconazole concentrations with a higher delay to reach concentrations > 2 mg/L in CAPA vs. IAPA patients (p = 0.045). Severe COVID-19 and influenza patients appeared very similar in terms of prevalence of IPA and outcome. The dramatic consequences on the patients’ prognosis emphasize the need for a better awareness in these particular populations.